Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.

Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).

Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain patients with head and neck ...

Through its PPIE initiative, the MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.

Evommune has secured exclusive rights outside Greater China to develop EVO570 from Hinova Pharmaceuticals in a deal worth up to $1.1bn.

PharmatrophiX and Circular Genomics have partnered to advance blood-based circular RNA biomarkers in neurodegenerative drug development programmes.

Biotech investor Stephan Christgau speaks about the key considerations when devising a clinical strategy that will attract investor attention.

AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of $750m.

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.